Bionomics receives Nasdaq bid price deficiency notice; has until Jan 7, 2025 to regain compliance

Neuphoria Therapeutics Inc.

Nasdaq notified Bionomics on July 11, 2024 that its ADS bid price closed below $1.00 for 30 consecutive business days.
Company has 180 calendar days (until Jan 7, 2025) to regain compliance by maintaining $1.00 closing bid for 10 consecutive days.
If not cured by Jan 7, 2025, Bionomics may qualify for a second 180-day period by meeting other listing standards and announcing a reverse stock split plan.
Failure to cure or qualify for extension could result in delisting from The Nasdaq Global Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.